Filana Therapeutics, Inc. (FLNA) — Working Capital to Net Assets Ratio
Filana Therapeutics, Inc. (FLNA) has a Working Capital to Net Assets ratio of 68.5% as of June 2026. Working capital of $43.56 Million (current assets of $83.72 Million minus current liabilities of $40.16 Million) is measured against net assets of $63.61 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See FLNA days of operational coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Filana Therapeutics, Inc. Working Capital to Net Assets (2022–2025)
This chart shows how Filana Therapeutics, Inc.'s Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of June 2026, the ratio stands at 68.5%, reflecting working capital of $43.56 Million against net assets of $63.61 Million USD. For the complete balance sheet picture, see FLNA total assets.
Annual Working Capital to Net Assets for Filana Therapeutics, Inc. (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Filana Therapeutics, Inc. from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read Filana Therapeutics, Inc. debt and liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 72.4% | $53.88 Million | $74.40 Million | $97.71 Million | $43.83 Million | ▼ -13.2 pp |
| 2024 | 85.6% | $124.78 Million | $145.70 Million | $136.53 Million | $11.75 Million | ▲ +1.7 pp |
| 2023 | 84.0% | $115.44 Million | $137.47 Million | $129.63 Million | $14.20 Million | ▼ -5.8 pp |
| 2022 | 89.7% | $204.16 Million | $227.54 Million | $211.23 Million | $7.06 Million | — |